Magnetocardiography as a Tool for Patients Presenting With Chest Pain - Pilot Study

August 3, 2015 updated by: Quantum Imaging Limited

Two Cohort, Pilot Study, to Identify Magnetocardiogram Characteristics That Can be Used to Classify Non Ischemic Chest Pain Patients and Myocardial Infarction Patients.

The purpose of this pilot research study is to identify the characteristics of magnetocardiograms that correlate with a non ischemic chest pain status and a myocardial infarction patient status. The study uses a non SQUID magnetocardiogram device.

Study Overview

Status

Completed

Conditions

Detailed Description

Magnetocardiography (MCG) is a passive, non-contact technique to measure the electromagnetic activity of the heart.

Heart muscle is controlled by electrical impulses that initiate contraction of the myocardium to pump blood around the body. A wave of depolarisation and repolarisation helps to coordinate the heart's activity which is usually measured using an electrocardiogram (ECG) which reflects the surface electrical manifestation of myocardial depolarisation and repolarisation

For every electrical signal there is a corresponding magnetic field, as defined by Faraday's law of induction, and it is this magnetic field that MCG measures.

There are two key advantages of looking at the magnetic field rather than the electrical signal. (1) The signal is not attenuated as it passes through the body, so information is not lost and (2) changes in the action potential (for example those caused by ischemia) are 'magnified' in the magnetic field so are easier to detect by sensors that are not in direct contact with the body.

SQUID MCG has been used widely in cardiology research, and previous clinical studies have shown that the technology has potential for the analysis of patients with coronary artery disease.

The aim of this pilot study is to identify characteristics of MCG that differentiate patients with non-ischaemic chest pain from those with a myocardial infarction.

.

Study Type

Observational

Enrollment (Actual)

41

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • West Yorkshire
      • Leeds, West Yorkshire, United Kingdom, LS2 9DF
        • Leeds Teaching Hospitals NHS Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients presenting in Accident and Emergency Department with chest pain of presumed ischemic origin

Description

Inclusion Criteria:

Non ischemic chest pain subject inclusion criteria

  • Subjects will be males or females over the age of 18.
  • Subjects will have experienced chest pain within the last 8 weeks and have been subsequently referred to the rapid access chest pain clinic (RACPC).
  • Subjects will have no coronary artery disease/ischemia as demonstrated by one of the following: MRI, myoview or stress echo within no less than 4 weeks prior to the magnetocardiogram (MCG) scan.
  • Subjects will have given written informed consent to participate in the study.

Myocardial Infarction subject inclusion criteria

  • Subjects will be males or females over the age of 18.
  • Subjects will have experienced chest pain and have been admitted to the cardiology unit.
  • Subjects will have an abnormal level of Troponin (≥50ng/l) taken at 12 hours following the onset of chest pain.
  • Subjects will be suitable to have an MCG scan taken within 48 hours of the onset of chest pain and prior to coronary angioplasty or any other surgical intervention.
  • Subjects will have given written informed consent to participate in the study.

Exclusion Criteria:

Non ischemic chest pain subject exclusion criteria

  • Subjects with symptoms suggestive of acute coronary syndrome that require further investigation.
  • Subjects who had an abnormal level of Troponin (≥50ng/l) - as determined by a test performed prior to referral to the RACPC.
  • Subjects who have a pacemaker or internal cardiac defibrillator.
  • Subjects with an active implantable device.
  • Subjects with ferrous implants in the torso including wires or ferrous stents.
  • Subjects who are pregnant.
  • Subjects who are unable to lie in a supine position.
  • Subjects with any comorbidity that prevents them being scanned.

Myocardial Infarction subject exclusion criteria

  • Subjects who have had a STEMI.
  • Patients with haemodynamic instability (dysrhythmia or hypotension).
  • Subjects who have had a revascularisation technique performed prior to an MCG scan.
  • Subjects who have a pacemaker or internal cardiac defibrillator.
  • Subjects with ferrous implants in the torso including wires or ferrous stents.
  • Subjects with an active implantable device.
  • Subjects who are pregnant.
  • Subjects who are unable to lie in a supine position.
  • Subjects with any comorbidity that prevents them being scanned.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Group 1 - Non ischemic chest pain
No coronary artery disease (CAD) as confirmed by myoview, MRI or stress echo. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
Group 2 - Myocardial infarction
Myocardial infarction confirmed by a troponin test (>50ng/l) 12 hours after the onset of chest pain. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Magnetocardiogram Characteristics in patients with chest pain
Time Frame: 1 hour
Quantitative comparison of magnetocardiogram characteristics of non ischaemic chest pain patients compared to those with an acute myocardial infarction
1 hour

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Device Safety
Time Frame: At time of scan for all patiients (Varies)
Any adverse effects, adverse device effects, Unanticipated serious device effects
At time of scan for all patiients (Varies)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mark Kearney, MBChB FRCP, Leeds Teaching Hospitals NHS Trust

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2015

Primary Completion (Actual)

July 1, 2015

Study Completion (Actual)

August 1, 2015

Study Registration Dates

First Submitted

January 12, 2015

First Submitted That Met QC Criteria

February 4, 2015

First Posted (Estimate)

February 10, 2015

Study Record Updates

Last Update Posted (Estimate)

August 4, 2015

Last Update Submitted That Met QC Criteria

August 3, 2015

Last Verified

February 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • QI CIP 001 Rev 001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe